IgA glomerulonephritis
Therapeutic area
Nephrology
Rare disease
Yes
- Definition
- Inflammation of a specific segment of glomeruli within the kidney.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- IgA glomerulonephritis
- Therapeutic area
- Nephrology
- IgA glomerulonephritis
- Berger's disease
- IgA Nephropathy
- IgA glomerulonephritis
- IgA nephropathy
- All therapeutic areas
- Nephrology
- Severity
- Severe
- Genetic
- Hereditary
- Inflammatory
- MONDO ID
- MONDO:0005342
- Parent condition
- MONDO:0002462
Related records
Broader conditions (15)
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Glomerular disorder
- Glomerulonephritis
- Hereditary disease
- Hereditary nephritis
- Human disease
- Inflammatory disease
- Inherited kidney disorder
- Kidney disorder
- Nephritis
- Urinary system disorder
Trials (164)
- "Steroids and Azathioprine Versus Steroids Alone in IgAN"
- A Clinical Research on the Use of Fecal Bacteria Transplantation for Treatment of IgA Nephropathy
- A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
- A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects
- A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
- A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
- A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
- A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
- A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
- A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
- A Phase IIa Study in Primary IgA Nephropathy Patients
- A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
- A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
- A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
- A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- A Study of Probiotics in IgA Nephropathy
- A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment
- A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
Approved drugs (3)
- Budesonide
- Iptacopan hydrochloride
- Sparsentan
Drugs in development (45)
- Acetoside Phase 2
- Aliskiren Phase 3
- Atacicept Phase 3
- Atorvastatin calcium Phase 2
- Atrasentan Phase 3
- Avacopan Phase 2
- Azathioprine Phase 3
- Batiraxcept Phase 2
- Blisibimod Phase 3
- Cemdisiran Phase 2
- Cyclophosphamide Phase 3
- Dapagliflozin Phase 3
- Enalapril Phase 2
- Felzartamab Phase 2
- Finerenone Phase 3
- Fostamatinib Phase 2
- Fostamatinib disodium Phase 2
- Hydroxychloroquine Phase 2
- Icosapent Phase 3
- Iptacopan Phase 3
Other linked drugs (2)
- Allopurinol
- Calcitriol